Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model
Authors:
Open Access
- 14 April 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0153508
Abstract
There are currently over 2.5 million breast cancer survivors in the United States and, according to the American Cancer Society, 10 to 20 percent of these women will develop recurrent breast cancer. Early detection of recurrence can avoid unnecessary radical treatment. However, self-examination or mammography screening may not discover a recurring cancer if the number of surviving cancer cells is small, while biopsy is too invasive and cannot be frequently repeated. It is therefore important to identify non-invasive biomarkers that can detect early recurrence. The present paper develops a mathematical model of cancer recurrence. The model, based on a system of partial differential equations, focuses on tissue biomarkers that include the plasminogen system. Among them, only uPAR is known to have significant correlation to its concentration in serum and could therefore be a good candidate for serum biomarker. The model includes uPAR and other associated cytokines and cells. It is assumed that the residual cancer cells that survived primary cancer therapy are concentrated in the same location within a region with a very small diameter. Model simulations establish a quantitative relation between the diameter of the growing cancer and the total uPAR mass in the cancer. This relation is used to identify uPAR as a potential serum biomarker for breast cancer recurrence.Keywords
Funding Information
- Directorate for Mathematical and Physical Sciences (0931642)
This publication has 82 references indexed in Scilit:
- Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × DocetaxelBMC Cancer, 2011
- MicroRNA-19 (miR-19) Regulates Tissue Factor Expression in Breast Cancer CellsJournal of Biological Chemistry, 2011
- Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammationBlood, 2010
- Do serum biomarkers really measure breast cancer?BMC Cancer, 2009
- Granulocyte Macrophage Colony-Stimulating Factor Inhibits Breast Cancer Growth and Metastasis by Invoking an Anti-Angiogenic Program in Tumor-Educated MacrophagesCancer Research, 2009
- A methodology for performing global uncertainty and sensitivity analysis in systems biologyJournal of Theoretical Biology, 2008
- Impact of aging on the biology of breast cancerCritical Reviews in Oncology/Hematology, 2008
- Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast CancerBreast Care, 2008
- Role of tumor-associated macrophages in tumor progression and invasionCancer and Metastasis Reviews, 2006
- Stromal fibroblasts in cancer initiation and progressionNature, 2004